Automate Your Wheel Strategy on MRK
With Tiblio's Option Bot, you can configure your own wheel strategy including MRK - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol MRK
- Rev/Share 25.7146
- Book/Share 20.7566
- PB 4.1794
- Debt/Equity 0.798
- CurrentRatio 1.6612
- ROIC 0.2431
- MktCap 218020510675.0
- FreeCF/Share 5.2238
- PFCF 16.7078
- PE 11.385
- Debt/Assets 0.372
- DivYield 0.0373
- ROE 0.3895
- Rating A-
- Score 4
- Recommendation Buy
- P/E Score 3
- DCF Score 5
- P/B Score 2
- D/E Score 1
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Resumed | MRK | Citigroup | -- | Neutral | -- | $95 | Oct. 13, 2025 |
| Downgrade | MRK | Berenberg | Buy | Hold | -- | $90 | Sept. 17, 2025 |
| Downgrade | MRK | Citigroup | Buy | Neutral | -- | $84 | May 14, 2025 |
| Initiation | MRK | Cantor Fitzgerald | -- | Neutral | -- | $85 | April 22, 2025 |
| Downgrade | MRK | Deutsche Bank | Buy | Hold | $128 | $105 | Feb. 18, 2025 |
| Downgrade | MRK | TD Cowen | Buy | Hold | $121 | $100 | Feb. 10, 2025 |
| Downgrade | MRK | Truist | Buy | Hold | -- | $110 | Jan. 8, 2025 |
| Downgrade | MRK | BMO Capital Markets | Outperform | Market Perform | $136 | $105 | Dec. 20, 2024 |
| Resumed | MRK | BofA Securities | -- | Buy | -- | $121 | Dec. 10, 2024 |
| Upgrade | MRK | HSBC Securities | Hold | Buy | -- | $130 | Dec. 4, 2024 |
News
Merck & Co., Inc. (MRK) Shareholder/Analyst Call Transcript
Published: November 10, 2025 by: Seeking Alpha
Sentiment: Neutral
Merck & Co., Inc. ( MRK ) Shareholder/Analyst Call November 9, 2025 7:01 PM EST Company Participants Peter Dannenbaum - Vice President of Investor Relations Dean Li - Executive VP & President of Merck Research Laboratories Joerg Koglin - Senior VP & Head of General Medicine - Global Clinical Development Jannie Oosthuizen - Senior VP & President Merck U.S. Human Health Conference Call Participants Taylor Hanley - JPMorgan Chase & Co, Research Division Daina Graybosch - Leerink Partners LLC, Research Division Nick Jennings - Goldman Sachs Group, Inc., Research Division Malcolm Hoffman - BMO Capital Markets Equity Research Vamil Divan …
Read More
Will Keytruda Aid MRK's Growth in 2026 After a Subdued Q3?
Published: November 10, 2025 by: Zacks Investment Research
Sentiment: Neutral
Merck leans on Keytruda's expanding cancer indications and new SC formulation to sustain growth momentum into 2026 after soft sales in Q3.
Read More
Here is What to Know Beyond Why Merck & Co., Inc. (MRK) is a Trending Stock
Published: November 07, 2025 by: Zacks Investment Research
Sentiment: Positive
Zacks.com users have recently been watching Merck (MRK) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Read More
Why Merck (MRK) is a Top Value Stock for the Long-Term
Published: November 04, 2025 by: Zacks Investment Research
Sentiment: Positive
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Read More
MRK Beats Q3 Earnings Estimates, Narrows 2025 Sales View, Stock Down
Published: October 30, 2025 by: Zacks Investment Research
Sentiment: Positive
Merck tops Q3 earnings and revenue estimates on strong oncology, new drugs and animal health sales, while narrowing its 2025 revenue outlook.
Read More
Merck & Co., Inc. (MRK) Q3 2025 Earnings Call Transcript
Published: October 30, 2025 by: Seeking Alpha
Sentiment: Neutral
Merck & Co., Inc. ( MRK ) Q3 2025 Earnings Call October 30, 2025 9:00 AM EDT Company Participants Peter Dannenbaum - Vice President of Investor Relations Robert Davis - Chairman, President & CEO Caroline Litchfield - Executive VP & CFO Dean Li - Executive VP & President of Merck Research Laboratories Conference Call Participants Asad Haider - Goldman Sachs Group, Inc., Research Division Geoffrey Meacham - Citigroup Inc., Research Division Akash Tewari - Jefferies LLC, Research Division Evan Seigerman - BMO Capital Markets Equity Research Daina Graybosch - Leerink Partners LLC, Research Division Christopher Schott - JPMorgan Chase & …
Read More
My Top 10 High-Yield Picks For November 2025: One Yields 9%+
Published: October 30, 2025 by: Seeking Alpha
Sentiment: Positive
I present a diversified selection of high-yield dividend stocks with strong income and growth potential, including CVX, VZ, MO, ARCC, and others. Each company was selected for sustainable dividends, attractive yields, reasonable payout ratios, and a proven record or potential for dividend growth. CVX and ARCC receive positive Wall Street ratings, while VZ and MO offer high yields and strong free cash flow, supporting portfolio income stability.
Read More
Merck Q3 financial results top estimates, company lowers revenue guidance
Published: October 30, 2025 by: Proactive Investors
Sentiment: Neutral
Merck & Co Inc (NYSE:MRK, ETR:6MK) on Thursday reported third quarter 2025 earnings and revenue that surpassed Wall Street expectations, lifted by strong demand for its cancer immunotherapy Keytruda, but reduced its full-year sales outlook to reflect lower estimated tariff costs, among other factors. The pharmaceutical company's revenue for the quarter rose 4% year over year to $17.28 billion, exceeding the $16.96 billion analyst consensus estimate provided by LSEG.
Read More
Merck (MRK) Reports Q3 Earnings: What Key Metrics Have to Say
Published: October 30, 2025 by: Zacks Investment Research
Sentiment: Positive
The headline numbers for Merck (MRK) give insight into how the company performed in the quarter ended September 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Read More
Merck: Wall Street Surprised By Q3 Strength, Keytruda Sales Surge
Published: October 30, 2025 by: Seeking Alpha
Sentiment: Positive
Merck published its financial results for Q3 2025 this morning. Strong demand for Winrevair from patients suffering from pulmonary arterial hypertension drove sales to $360 million in the third quarter of 2025, up 141.6% year-on-year. Of MRK's vaccine franchise, its "gem" remains Capvaxive, which generated sales of $244 million for the quarter, a sharp 419.1% rise from the same period a year ago.
Read More
The setup on earnings beyond tech
Published: October 29, 2025 by: CNBC Television
Sentiment: Neutral
The Investment Committee debate some non-mega cap names reporting in the next 24 hours.
Read More
Merck and Eisai Provide Update on Phase 3 LEAP-012 Trial in Unresectable, Non-Metastatic Hepatocellular Carcinoma
Published: October 29, 2025 by: Business Wire
Sentiment: Neutral
RAHWAY, N.J. & NUTLEY, N.J.--(BUSINESS WIRE)---- $MRK #MRK--Merck and Eisai Provide Update on Phase 3 LEAP-012 Trial in Unresectable, Non-Metastatic Hepatocellular Carcinoma.
Read More
European Commission Approves KEYTRUDA® (pembrolizumab) as Part of a Treatment Regimen for Adults with Resectable Locally Advanced Head and Neck Squamous Cell Carcinoma (LA-HNSCC) Expressing PD-L1 (CPS >1)
Published: October 29, 2025 by: Business Wire
Sentiment: Neutral
RAHWAY, N.J.--(BUSINESS WIRE)---- $MRK #MRK--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced that the European Commission (EC) has approved KEYTRUDA® (pembrolizumab), Merck's anti-PD-1 therapy, as monotherapy for the treatment of resectable locally advanced head and neck squamous cell carcinoma (LA-HNSCC) as neoadjuvant treatment, continued as adjuvant treatment in combination with radiation therapy with or without concomitant cisplatin and then as monotherapy in adul.
Read More
Buy, Sell or Hold MRK Stock Ahead of Q3 Earnings? Things to Know
Published: October 28, 2025 by: Zacks Investment Research
Sentiment: Negative
MRK faces pressure from weak vaccine sales and rising competition, but strong oncology growth and new launches could support a rebound.
Read More
Healthy Returns: What to expect from Eli Lilly, Merck, Gilead and AbbVie third-quarter earnings
Published: October 28, 2025 by: CNBC
Sentiment: Positive
Eli Lilly, Merck, Gilead, Bristol Myers Squibb and AbbVie, among other pharmaceutical companies, are slated to report third-quarter earnings this week.
Read More
Are You Looking for a High-Growth Dividend Stock?
Published: October 27, 2025 by: Zacks Investment Research
Sentiment: Positive
Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Merck (MRK) have what it takes?
Read More
What's in Store for These 5 Pharma Bigwigs This Earnings Season?
Published: October 27, 2025 by: Zacks Investment Research
Sentiment: Neutral
As earnings season accelerates, pharma heavyweights LLY, MRK, ABBV, BMY and GILD prepare to reveal their Q3 results amid a strong sector start.
Read More
JNJ vs. MRK: Which Blue-Chip Pharma Stock Should Be in Your Portfolio?
Published: October 27, 2025 by: Zacks Investment Research
Sentiment: Positive
J&J's diversified growth, strong pipeline, and robust balance sheet position it as a steadier long-term pick over Merck's Keytruda-dependent outlook.
Read More
Merck (MRK) Q3 Earnings Preview: What You Should Know Beyond the Headline Estimates
Published: October 27, 2025 by: Zacks Investment Research
Sentiment: Neutral
Get a deeper insight into the potential performance of Merck (MRK) for the quarter ended September 2025 by going beyond Wall Street's top-and-bottom-line estimates and examining the estimates for some of its key metrics.
Read More
3 Healthcare Stocks That Are Screaming Deals Right Now
Published: October 26, 2025 by: The Motley Fool
Sentiment: Positive
DaVita's recession-resistant business is growing internationally, but shares continue to trade at a heavily discounted valuation. Merck could be in for a major move if the pharma can soften the blow of an upcoming patent expiration.
Read More
Merck Q3 Earnings Preview: Issues That Will Dominate The Agenda
Published: October 24, 2025 by: Seeking Alpha
Sentiment: Neutral
Merck & Co., Inc. faces a pivotal Q3 earnings report as Keytruda's patent expiration looms and pipeline diversification efforts accelerate. MRK's oncology pipeline, including Keytruda Qlex and multiple ADCs, aims to offset future revenue loss, but execution risk remains high. Non-oncology segments face setbacks, with Gardasil sales declining and new launches like Winrevair underperforming expectations.
Read More
Merck's Non-Oncology Drugs Q3 Performance: What to Expect
Published: October 24, 2025 by: Zacks Investment Research
Sentiment: Neutral
MRK expects new products like Capvaxive, Winrevair, and the Animal Health business to support its top-line growth in the third quarter.
Read More
5 Best Dividend Stocks in the S&P 500
Published: October 23, 2025 by: 24/7 Wall Street
Sentiment: Positive
Income investors rarely chase the loudest headlines.
Read More
eschbach's Shiftconnector® Helps Power Merck's Visual Factory to Drive Greater Transparency, Agility, and Supply Chain Resilience
Published: October 23, 2025 by: PRNewsWire
Sentiment: Neutral
BOSTON , Oct. 23, 2025 /PRNewswire/ -- eschbach is pleased to share that Merck (NYSE: MRK), known as MSD outside the United States and Canada, has selected Shiftconnector to improve how it uses digital tools in manufacturing. By integrating Shiftconnector into its established visual factory framework, Merck is enhancing its ability to deliver real-time, actionable insights across global operations.
Read More
Merck (MRK) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
Published: October 23, 2025 by: Zacks Investment Research
Sentiment: Neutral
Merck (MRK) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Read More
Flare Therapeutics Announces Clinical Trial Collaboration and Supply Agreement with Merck to Evaluate FX-909 in Combination with KEYTRUDA® (pembrolizumab) in New Cohort of Ongoing Phase 1 Trial in Metastatic Urothelial Cancer
Published: October 21, 2025 by: GlobeNewsWire
Sentiment: Neutral
CAMBRIDGE, Mass., Oct. 21, 2025 (GLOBE NEWSWIRE) -- Flare Therapeutics Inc. (FlareTx), a clinical-stage biotechnology company targeting transcription factors to discover precision medicines for oncology and other therapeutic areas, today announced that it has entered into a clinical trial collaboration and supply agreement with Merck (known as MSD outside of the United States and Canada). FX-909, a first-in-class orally available small molecule inhibitor of PPARG, the master regulator of the luminal lineage, will be evaluated in combination with KEYTRUDA ® (pembrolizumab), Merck's anti-PD-1 (programmed cell death receptor-1) therapy, in a new cohort within the company's ongoing Phase 1 study in …
Read More
Systematic Review of 15 Studies Focused on Epidemiology and Antimicrobial Resistance of Pneumococcal Serotypes Covered by CAPVAXIVE® (Pneumococcal 21-valent Conjugate Vaccine) in U.S. Adults
Published: October 21, 2025 by: Business Wire
Sentiment: Neutral
RAHWAY, N.J.--(BUSINESS WIRE)---- $MRK #MRK--Systematic Review of 15 Studies Focused on Epidemiology and Antimicrobial Resistance of Pneumococcal Serotypes Covered by CAPVAXIVE in U.S. Adults.
Read More
My Top 3 Pharma Stocks
Published: October 20, 2025 by: Seeking Alpha
Sentiment: Positive
Obesity, type 2 diabetes, and cancer continue to grow across the globe, but pharma stocks remain off the radars of many investors. Many of them consistently beat the Street's consensus estimates and offer dividend yields even higher than IT, as well as oil and gas stocks. In this article, I reveal my top 3 Big Pharma players.
Read More
Goldman Sachs Reveals Sectors With Top 2026 Payouts: 5 Strong Buys
Published: October 20, 2025 by: 24/7 Wall Street
Sentiment: Neutral
Founded in 1869, Goldman Sachs is the world's second-largest investment bank by revenue and is ranked 55th on the Fortune 500 list of the largest United States corporations by total revenue.
Read More
2 Beaten-Down Stocks to Buy and Hold for the Next Decade
Published: October 20, 2025 by: The Motley Fool
Sentiment: Positive
The market is forward-looking, but investors who earn better-than-average returns often look even further into the future and identify opportunities that are currently being overlooked. That means, among other things, buying shares of companies that are lagging the market but can bounce back over the midterm and beyond.
Read More
About Merck & Co., Inc. (MRK)
- IPO Date 1978-01-13
- Website https://www.merck.com
- Industry Drug Manufacturers - General
- CEO Robert M. Davis
- Employees 73000